stockrow
Friday 6 November 2026
Export APYX’s income statement to Excel — free account
Apyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024.
- Revenue
- +8.95%
- EPS
- +20.0%
- Free cash flow
- +53.2%
- Total debt
- +2.74%
Quarter to September 2026, against a year earlier
2.93
0.13
−4.25%
Follow APYX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(76.88%) | (77.27%) | (93.11%) | (104.67%) | |
Piotroski F-Score |
4 | 5 | 4 | 5 | |
| (17.03%) | (14.89%) | (14.48%) | (14.17%) | ||
ROIC |
(22.44%) | (15.79%) | (11.76%) | (10.33%) | |
Return on Tangible Assets |
(22.81%) | (19.27%) | (18.81%) | (18.68%) | |
Average Days of Receivables |
115.87 | 83.28 | 85.07 | 91.13 | |
Free Cash Flow per Share |
(0.22) | (0.21) | (0.25) | (0.20) | |
Free Cash Flow |
(9.11) | (8.99) | (11.05) | (8.89) | |
Capital Expenditures |
(1.11) | (1.12) | (0.92) | (0.67) | |
| Other line items | |||||
Cash ROIC |
(11.19%) | (11.33%) | (14.92%) | (12.46%) | |
Accounts Receivable Turnover |
3.28 | 4.58 | 4.70 | 4.28 | |
Accounts Payable Turnover |
6.98 | 8.35 | 8.39 | 6.47 | |
Inventory Turnover |
2.45 | 2.39 | 2.25 | 2.06 | |
Average Days of Payables |
56.37 | 46.58 | 37.49 | 58.89 | |
Days of Inventory on Hand |
158.57 | 168.96 | 183.95 | 200.33 | |
Tax Rate |
0.02 | 0.04 | 0.06 | 0.06 | |
Research and Development Expense of Revenue |
6.38% | 5.96% | 5.65% | 5.63% | |
Selling, General and Administrative Expense of Revenue |
68.35% | 64.89% | 63.90% | 0.00% | |
Share Based Compensation of Revenue |
3.79% | 3.33% | 4.14% | 4.43% | |
Interest Coverage |
(1.15) | (0.77) | (0.63) | (0.59) | |
Operating CF/Net income |
0.71 | 0.86 | 1.17 | 0.98 | |
Depreciation/Fixed assets |
0.28 | 0.32 | 0.37 | 0.37 | |
Capex/Depreciation |
(1.70) | (1.56) | (1.17) | (0.83) | |
Revenue per Share |
1.29 | 1.28 | 1.33 | 1.35 | |
Operating CF per Share |
(0.19) | (0.18) | (0.23) | (0.19) | |
Capex per Share |
(0.03) | (0.03) | (0.02) | (0.02) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026